PreciThera is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology. The Company focuses on heterogeneous genetic disorders that primarily manifest in bone dysfunction. In depth understanding of disease mechanism will allow PreciThera’s targeted strategies to meaningfully impact both the skeletal symptoms as well as the extraskeletal issues found in these patients.
Latest funding size
Time since last funding
|10 months ago|
|CTI Life Sciences Fund, Fonds de solidarité FTQ, Sanderling Ventures, Arix Bioscience, Emerillon Capital|